This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Olmesartan Medoxomil in Atherosclerosis

This study has been completed.
Information provided by:
Daiichi Sankyo, Inc. Identifier:
First received: September 12, 2005
Last updated: December 12, 2007
Last verified: December 2007
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.

Condition Intervention Phase
Essential Hypertension Atherosclerotic Cardiovascular Disease Drug: Olmesartan medoxomil Drug: Atenolol Drug: Hydrochlorothiazide Drug: olmesartan medoxomil Drug: atenolol Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo, Inc.:

Primary Outcome Measures:
  • Change of intima media thickness of the common carotid artery on the leading side of the neck.

Secondary Outcome Measures:
  • -Change in plaque volume in the common carotid artery or the carotid bulb.
  • -Change of intima media thickness of the common carotid artery.
  • -Changes of diastolic and systolic blood pressure.
  • -Safety and tolerability

Enrollment: 165
Study Start Date: November 2001
Study Completion Date: February 2006
Arms Assigned Interventions
Experimental: 1
olmesartan medoxomil
Drug: Olmesartan medoxomil Drug: Hydrochlorothiazide
Drug: olmesartan medoxomil
Active Comparator: 2
Drug: Atenolol Drug: Hydrochlorothiazide
Drug: atenolol


Ages Eligible for Study:   35 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mean sitting sBP and dBP prior to randomization of 140-180/90-105 mmHg
  • Increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral atherosclerotic disease stage IIa or lower; b) diabetes mellitus type 2; c) left ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction, stroke or TIA
  • Intima-media thickness of the common carotid artery greater than or equal to 0.8 and less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl

Exclusion Criteria:

  • Body mass index > 30
  • Any type of known secondary hypertension
  • Electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (< 50/min)
  • Obstructive pulmonary disease
  • Claudicatio intermittens
  • History or clinical evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial
  • Hypersensitivity or contraindication to ARBs, Beta-Blockers, HCTZ or any cross allergy
  • Pre-treatment with ARBs or ACE inhibitors within 6 months prior to screening
  • Treatment with disallowed medication
  • Pregnant or breastfeeding females or females of childbearing potential without adequate contraception
  • History of alcohol and/or drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00185185

Munich, Germany
Sponsors and Collaborators
Sankyo Pharma Gmbh
Principal Investigator: Prof. Klaus O Stumpe, MD Medizinische Poliklinik der Friedrich-Wilhelms-Universitat, Bonn, Germany
  More Information

Responsible Party: Petra Laeis, Daichi Sankyo Europe, GmbH Identifier: NCT00185185     History of Changes
Other Study ID Numbers: SE-866/27
Study First Received: September 12, 2005
Last Updated: December 12, 2007

Additional relevant MeSH terms:
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Olmesartan Medoxomil
Antihypertensive Agents
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Anti-Arrhythmia Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents processed this record on September 21, 2017